Compare BioNano Genomics Inc (BNGO) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Expeditors International of Wshngtn Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Expeditors International of Wshngtn Inc trades at $177.32 (market cap $23.31B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 1765.9× BioNano Genomics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | EXPD | |
|---|---|---|
Market Cap | $13.20M | $23.31B |
Sector | Health | Industrials |
52-Week High | $4.92 | $178.22 |
52-Week Low | $1.09 | $111.37 |
Enterprise Value | $15.81M | $22.56B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
EXPD trades at $175.50, up 2.02% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, revenue growth to $11.07B in 2025, and impressive ROE of 36.59%. Recent dividend payments and positive analyst coverage highlight financial stability, though valuation metrics appear elevated with P/E of 28.35.
Outlook remains positive with earnings momentum and e-commerce tailwinds, but risks include stretched valuation, mixed analyst sentiment (only 12% buy ratings), and economic sensitivity. The stock trades above consensus price target of $159, suggesting limited near-term upside potential despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
